As of Sept. 1, 2008 Wülfing Pharma GmbH operates under the name Haupt Pharma Wülfing GmbH
An Enterprise of the Haupt Pharma Group
Invita AG has merged its portfolio companies Haupt Pharma, AMAREG and Wülfing Pharma as of September 1, 2008.
With the merger of these pharmaceutical contract manufacturers and developers the most efficient company in its sector in Europe will be established with about 1.500 employees and a turnover of €180 million.
Haupt Pharma will have an even broader range of manufacturing technologies for its customers, with the result that Haupt Pharma will expand the range of services in the fields of galenic and analytical development, clinical sample production and marketing authorisations.
Haupt Pharma Wülfing GmbH will continue to offer its well-known full service as well as its certified quality and on schedule delivery at favourable conditions.